

TABLE OF CONTENTS

List of Tables.....	i
List of Figure.....	iii
List of Abbreviations and symbol.....	xi
Chapter 1	
1.1 Introduction	1
1.2 Anatomy and Physiology of Human Respiratory Tract	2
1.3 Deposition mechanisms of inhaled particles.....	4
1.4 Barriers in Pulmonary Delivery	5
1.5 Delivery devices	8
1.5.1 Nebulizers.....	8
1.5.2 Pressurized Metered-Dose Inhalers.....	10
1.5.3 Dry Powder Inhalers.....	12
1.5.4 Unit-dose devices	16
1.5.5 Multi-dose devices.....	17
1.6 Importance of the inspiratory airflow.....	19
1.7 Future research and new developments	20
1.7.1 Formulation of dry powder inhalers.....	21
1.7.1.1 Nature of excipients	21
1.7.1.2 Blending	23
1.8 Nanocarriers for pulmonary delivery	24
1.8.1 Nanoparticle for pulmonary drug formulations.....	24
1.8.2 Liposomal Nanocarrier Formulations.....	26
1.8.3 Biodegradable microspheres.....	27
1.8.4 Large porous particles	28
1.9 Toxicity considerations of nanocarrier formulations.....	28
1.10 References	30
Chapter 2	
2.1 Cystic fibrosis.....	39

2.2 Pathophysiology of cystic fibrosis	42
2.2.1 Airway surface liquid (ASL) and Ion Transport Defects	43
2.2.2 Human Cell-Culture Models	44
2.2.3 Animal Models	45
2.2.4 Human Studies	47
2.2.5 Extrapulmonary CF Disease Pathophysiology	48
2.3 Bacterial infection	49
2.4 Treatment of CF	50
2.4.1 Ion Transport Therapies	50
2.4.2 Antiinflammatory therapies	51
2.4.3 Antimicrobial Drugs	52
2.4.4 Airway Clearance	53
2.4.5 Lung transplantation	53
2.4.6 Pancreatic enzyme replacements	53
2.4.7 Molecular Therapies	53
2.4.8 Gene therapy	54
2.4.8.1 CFTR cDNA delivery	55
2.4.8.2 RNA interference-mediated gene silencing	55
2.5 Challenges in drug delivery to the cystic fibrotic lungs	56
2.5.1 Cystic fibrosis sputum	56
2.5.1.1 Physical barrier	57
2.5.1.2 Chemical and biological barrier	57
2.5.1.3 Bacterial barrier	58
2.5.1.4 Mucociliary clearance	58
2.5.2 Cellular challenges	58
2.5.2.1 Bacterial drug resistance	59
2.5.2.2 Challenges in gene therapy	59
2.6 New drug delivery approaches	60
2.6.1 Antibiotics encapsulated Liposomal formulaions	60
2.6.2 Application of external forces to enhance Nanoparticles penetration	60
2.6.3 Mucolytics pretreatment	61
2.6.4 Surface-modified nanoparticles	61

2.6.5 Co-administration with agents that influence the cystic fibrosis sputum	62
2.7 Research envisioned.....	64
2.8 Objectives of the proposed work.....	67
2.9 pDNA and Drug profile.....	68
2.9.1 pDNA profile	68
2.9.1.1 piRIS2-EGFP CFTR plasmid	68
2.9.1.2 pcDNA-3 LUC-WT plasmid	69
2.9.2 Netilmicin sulfate	69
2.10 References	74
Chapter 3	
3.1 Introduction	89
3.1.1. Analytical method validation.....	89
3.1.1.1 Validation parameters.....	90
3.1.1.1.1 Specificity	90
3.1.1.1.2 Linearity and range.....	90
3.1.1.1.3 Accuracy	90
3.1.1.1.4 Precision	91
3.1.1.1.5 Limit of detection	92
3.1.1.1.6 Limit of quantitation.....	92
3.1.1.1.7 Robustness.....	93
3.2 Analytical method for estimation of Netilmicin sulfate.....	93
3.2.1 Materials.....	94
3.2.2 Reagents	94
3.2.3 Ultraviolet (UV) Spectrophotometric method for Estimation of Netilmicin sulfate in Bulk and Formulation.....	95
3.2.3.1 Instrumentation	95
3.2.3.2 Selection of media	95
3.2.3.3 Analytical method development for Netilmicin sulfate.....	95
3.2.3.4 Preparation of Netilmicin Sulfate stock solution.....	95
3.2.3.5 Calibration curve	95
3.2.3.6 Analytical method validation.....	96

3.2.3.7 Estimation from formulations.....	97
3.3 Analytical method for estimation of rhodamine B and 6-coumarin.....	97
3.3.1 Materials.....	97
3.3.2 Instrumentation.....	97
3.3.3 Preparation of stock solutions.....	98
3.3.4 Calibration curve.....	98
3.4 Estimation of plasmid DNA (pDNA).....	98
3.4.1 Reagents.....	99
3.4.2 Instrument.....	99
3.4.3 Calibration curve.....	99
3.5 Protein Assay.....	100
3.5.1 Reagents.....	100
3.5.2 Procedure.....	100
3.6 Results and discussion.....	100
3.6.1 Analytical method of estimation for netilmicin sulfate.....	100
3.6.1.1 Calibration curve.....	101
3.6.1.2 Analytical method validation of netilmicin sulfate.....	101
3.6.2 Analytical method for estimation of rhodamine B and 6-coumarin.....	109
3.6.3 Estimation of plasmid DNA (pDNA).....	112
3.6.4 Protein Assay.....	114
3.7 Conclusion.....	116
3.8 References.....	116
Chapter 4	
4.1 Transformation of pDNA in bacterial strain E. Coli Top 10.....	119
4.2 Plasmid Amplification and Isolation.....	122
4.3 Plasmid Purification (7).....	126
4.4 Gel retardation assay.....	127
4.5 Confirmation of plasmid by restriction enzymes:.....	127
4.6 Results and discussion.....	128
4.7 Conclusion.....	131
4.8 References.....	132

Chapter 5	136
5.1 Introduction	133
5.2 Formulation and development of Netilmicin sulfate loaded NPs	135
5.2.1 Materials	135
5.2.2 Development of drug-loaded NPs	136
5.2.3 Experimental design	136
5.2.4 Nanoparticle characterization	139
5.3 Formulation and development of plasmid loaded NPs	145
5.3.1 Materials	145
5.3.2 Development of pDNA loaded NPs	145
5.3.3 Nanoparticle characterization	146
5.4 Results and discussion	153
5.4.1 Development of Netilmicin sulfate loaded NPs	153
5.4.2 Development of pDNA loaded NPs	181
5.5 Conclusion	205
5.6 References	206
Chapter 6	217
6.1 Introduction	217
6.2 Materials	219
6.3 Preparation and characterization of dry powder inhaler formulation	219
6.3.1 Residual water content	220
6.3.2 Scanning electron microscopy (SEM)	220
6.3.3 Antibacterial activity	220
6.3.4 Luciferase assay	221
6.3.5 Animals	222
6.3.6 Particles uptake by rat alveolar macrophage	222
6.3.7 Particle deposition and clearance in rat lungs	222
6.3.8 Safety studies	223
6.3.8.1 Cytotoxicity study	223

6.3.8.2 TEER analysis	224
6.3.8.3 Bronchoalveolar lavage (BAL) studies	224
6.3.9 Lung histology	225
6.3.10 Stability study	225
6.3.11 Statistical analysis	225
6.4 Results and discussion	225
6.4.1 Lyophilization of NPs	225
6.4.2 Characterization of DPI	225
6.4.3 Antibacterial activity	229
6.4.4 Luciferase assay	232
6.4.5 Particles uptake by rat alveolar macrophage	233
6.4.6 Particle deposition and clearance in rat lungs	235
6.4.7 Safety study	236
6.4.8 Stability study	240
6.5 Conclusion	241
6.6 References	242
Chapter 7	245
Certificate	
List of presentations and publications	